Trial · NCT03492281
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants | Placebo | -1.3 | Standard Error 0.14 | micturitions per 24 hours | |
| Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants | Vibegron 75 mg | -1.8 | Standard Error 0.14 | micturitions per 24 hours | |
| Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants | Tolterodine ER 4 mg | -1.6 | Standard Error 0.15 | micturitions per 24 hours | |
| CFB at Week 12 in the Average Number of Urge Urinary Incontinence (UUI) Episodes Per 24 Hours in OAB Wet Participants | Placebo: OAB Wet | -1.4 | Standard Error 0.13 | UUI episodes per 24 hours | |
| CFB at Week 12 in the Average Number of Urge Urinary Incontinence (UUI) Episodes Per 24 Hours in OAB Wet Participants | Vibegron 75 mg: OAB Wet | -2.0 | Standard Error 0.13 | UUI episodes per 24 hours | |
| CFB at Week 12 in the Average Number of Urge Urinary Incontinence (UUI) Episodes Per 24 Hours in OAB Wet Participants | Tolterodine ER 4 mg: OAB Wet | -1.8 | Standard Error 0.14 | UUI episodes per 24 hours | |
| CFB at Week 12 in the Average Number of Urgency Episodes Over 24 Hours in All OAB Participants | Placebo | -2.0 | Standard Error 0.19 | urgency episodes over 24 hours | |
| CFB at Week 12 in the Average Number of Urgency Episodes Over 24 Hours in All OAB Participants | Vibegron 75 mg | -2.7 | Standard Error 0.19 | urgency episodes over 24 hours | |
| CFB at Week 12 in the Average Number of Urgency Episodes Over 24 Hours in All OAB Participants | Tolterodine ER 4 mg | -2.5 | Standard Error 0.21 | urgency episodes over 24 hours | |
| Percentage of OAB Wet Participants With at Least a 75% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Placebo: OAB Wet | Unadjusted | 36.8 | percentage of participants | |
| Percentage of OAB Wet Participants With at Least a 75% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Vibegron 75 mg: OAB Wet | Unadjusted | 52.4 | percentage of participants | |
| Percentage of OAB Wet Participants With at Least a 75% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Tolterodine ER 4 mg: OAB Wet | Unadjusted | 47.6 | percentage of participants | |
| Percentage of OAB Wet Participants With at Least a 75% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Placebo: OAB Wet | Adjusted for sex | 32.8 | percentage of participants | |
| Percentage of OAB Wet Participants With at Least a 75% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Vibegron 75 mg: OAB Wet | Adjusted for sex | 49.3 | percentage of participants | |
| Percentage of OAB Wet Participants With at Least a 75% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Tolterodine ER 4 mg: OAB Wet | Adjusted for sex | 42.2 | percentage of participants | |
| Percentage of OAB Wet Participants With a 100% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Placebo: OAB Wet | Unadjusted | 22.5 | percentage of participants | |
| Percentage of OAB Wet Participants With a 100% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Vibegron 75 mg: OAB Wet | Unadjusted | 28.8 | percentage of participants | |
| Percentage of OAB Wet Participants With a 100% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Tolterodine ER 4 mg: OAB Wet | Unadjusted | 26.6 | percentage of participants | |
| Percentage of OAB Wet Participants With a 100% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Placebo: OAB Wet | Adjusted for sex | 19.0 | percentage of participants | |
| Percentage of OAB Wet Participants With a 100% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 | Vibegron 75 mg: OAB Wet | Adjusted for sex | 25.3 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03492281/results